Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 6/20 | 0.51 |
| ▸ | ME1 | P48163 | 6/20 | 0.51 |
| ▸ | ME3 | Q16798 | 6/20 | 0.51 |
| ▸ | BPTF | Q12830 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261852 | 1.00 | PLD1 (0.53) | PLD1ME2ME1ME3BPTF | |
| Hydrochloric Acid SCHEMBL18740405 | 0.98 | PLD1 (0.51) | PLD1ME2ME1ME3BPTF | |
| SCHEMBL18768735 | 0.93 | CHRNB2 (0.51) | PLD1ME2ME1ME3BPTF | |
| SCHEMBL11956907 | 0.81 | UBE2T (0.54) | ME2ME1ME3DRD4ALDH1A1 | |
| SCHEMBL17640839 | 0.78 | SRC (0.57) | GPR119 | |
| SCHEMBL25257007 | 0.78 | PLD1 (0.53) | PLD1BPTFGPR119HTR2CALDH1A1 | |
| SCHEMBL3413013 | 0.78 | PLD1 (0.53) | PLD1BPTFGPR119HTR2CALDH1A1 | |
| SCHEMBL194226 | 0.78 | HTR3A (0.57) | PLD1BPTFGPR119HTR2CALDH1A1 | |
| SCHEMBL82373 | 0.78 | BPTF (0.64) | PLD1BPTFDRD4GPR119HTR2C | |
| SCHEMBL23458791 | 0.78 | PLD1 (0.53) | PLD1BPTFGPR119HTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-12-26 | — | — | US | disclosed |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4149939-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2017066366-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066366-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066368-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160016941-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970223-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164756-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
| EP-1243268-A1 | MEDICINAL COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1156045-A1 | AMIDE DERIVATIVES AND DRUG COMPOSITIONS | Nippon Shinyaku Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | PLD1 1286/4885ME2 2492/4885ME1 4337/4885 |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | PLD1 3114/4885ME2 2477/4885ME1 1267/4885 |
| US-12286424-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS1, LGALS3BP | PLD1 4007/4885ME2 4360/4885ME1 4183/4885 |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | PLD1 4007/4885ME2 4360/4885ME1 4183/4885 |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | PLD1 3114/4885ME2 355/4885ME1 1013/4885 |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | PLD1 1286/4885ME2 2492/4885ME1 4337/4885 |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | PLD1 1040/4885ME2 2809/4885ME1 4520/4885 |
| US-20160016941-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | PLD1 1040/4885ME2 2809/4885ME1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.